Lavie Bio will
offer Yalos™ (formerly Thrivus™) to farmers growing spring wheat,
durum and barley across the US and Canada in 2024
REHOVOT, Israel, Nov. 28,
2023 /PRNewswire/ -- Lavie Bio Ltd., a
subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading
ag-biological company committed to elevating food quality,
sustainability, and agricultural productivity through
microbiome-based innovations, is pleased to announce the expansion
of its microbiome-based product for spring wheat, now rebranded as
Yalos™ (formerly Thrivus™), to include durum and barley,
significantly broadening its potential market reach. This expansion
follows very successful field trials conducted in the US in 2023 in
durum and barley, which generated on average over 7% of yield
increase. Yalos™ is a seed treatment that enhances production by
improving soil nutrients, reducing environmental stress, and
increasing yields. It aims to boost yield in all small grains,
starting with spring wheat, durum, and barley.
The 2023 trials exceeded expectations with 86% success rate,
surpassing industry standards in extensive large-acre
trials. Yalos™ demonstrated its efficacy by delivering an
average production improvement of 8.3% in Durum and 6.6% in Barley.
This expansion increases the product's addressable market in the US
and Canada by ~40% from 25 million
acres to 35 million acres.
Yalos™ combines two natural microbes discovered by Lavie Bio's advanced BDD platform, powered by
Evogene's MicroBoost AI tech-engine. This platform provides
deep insights into microbe functions, allowing Lavie Bio to develop a strong portfolio of
high-performance, cost-effective bio-inoculants and bio-pesticides
like Yalos™.
Chad Rubbelke, owner at
Rubbelke Farms asserts "Yalos™ has been impressive
on our farm. As a farmer and research provider it is unusual
to see a product perform as well as Yalos™.
Yalos's performance has been consistent over several different
environmental conditions and years. In my mind Yalos™ is a strong
competitor in the biological market and pays for itself
yearly."
"We are very satisfied with these results from our 2023 field
trials enabling us to offer our product to durum & barley
growers in 2024." states Amit
Noam, Lavie Bio's CEO,
"As Lavie Bio charts its course for 2024, the company remains
dedicated to commercial growth by expanding to additional crops
across the United States,
Canada and beyond. Lavie Bio continues to lead the agricultural
innovation frontier, championing sustainable practices and
enhancing crop yields.
About Lavie Bio Ltd.
Lavie Bio, a subsidiary of
Evogene Ltd., aims to improve food quality, sustainability, and
agriculture productivity by introducing microbiome-based
ag-biological products. Lavie Bio
utilizes a proprietary computational predictive platform, the BDD
platform, powered by Evogene's proprietary MicroBoost AI
tech-engine, harnessing the power of big data, artificial
intelligence, and advanced informatics for the discovery,
optimization and development of bio-stimulant and bio-pesticide
products.
For more information, please visit www.lavie-bio.com.
About Evogene Ltd.
Evogene (Nasdaq: EVGN, TASE: EVGN) is a computational biology
company aiming to revolutionize the development of
life-science-based products by utilizing cutting-edge technologies
to increase the probability of success while reducing development
time and cost. Evogene established three unique tech-engines –
MicroBoost AI, ChemPass AI and GeneRator AI –
leveraging Big Data and Artificial Intelligence and incorporating
deep multidisciplinary understanding in life sciences. Each
tech-engine is focused on the discovery and development of products
based on one of the following core components: microbes
(MicroBoost AI), small molecules (ChemPass AI), and
genetic elements (GeneRator AI).
Evogene uses its tech-engines to develop products through
subsidiaries and strategic partnerships. Evogene's subsidiaries
currently utilize the tech-engines to develop human
microbiome-based therapeutics by Biomica, ag-biologicals by
Lavie Bio, ag-chemicals by
AgPlenus, medical cannabis products by Canonic and castor
varieties, for the biofuel and other industries, by Casterra.
For more information, please visit www.evogene.com.
Forward-Looking Statements
This press release contains "forward-looking statements"
relating to future events. These statements may be identified by
words such as "may", "could", "expects", "hopes" "intends",
"anticipates", "plans", "believes", "scheduled", "estimates",
"demonstrates" or words of similar meaning. For example, Evogene
and its subsidiaries are using forward-looking statement in this
press release when it discusses Yalos™ ability to enhance
production by improving soil nutrients, reducing environmental
stress, and increasing yields. Such statements are based on current
expectations, estimates, projections and assumptions, describe
opinions about future events, involve certain risks and
uncertainties which are difficult to predict and are not guarantees
of future performance. Therefore, actual future results,
performance or achievements of Evogene and its subsidiaries may
differ materially from what is expressed or implied by such
forward-looking statements due to a variety of factors, many of
which are beyond the control of Evogene and its subsidiaries,
including, without limitation, the current war between Israel and Hamas and any worsening of the
situation in Israel such as
further mobilizations or escalation in the northern boarder of
Israel, and those risk factors
contained in Evogene's reports filed with the applicable securities
authority. In addition, Evogene and its subsidiaries rely, and
expect to continue to rely, on third parties to conduct certain
activities, such as their field-trials and pre-clinical studies,
and if these third parties do not successfully carry out their
contractual duties, comply with regulatory requirements or meet
expected deadlines, Evogene and its subsidiaries may experience
significant delays in the conduct of their activities. Evogene and
its subsidiaries disclaim any obligation or commitment to update
these forward-looking statements to reflect future events or
developments or changes in expectations, estimates, projections,
and assumptions.
Evogene Investors' Contact:
Rachel Pomerantz Gerber, Head of Investor
Relations at Evogene
Email: rachel.pomerantz@evogene.com
Tel: +972-8-9311901
Logo -
https://mma.prnewswire.com/media/945133/lavie_bio.jpg
Logo - https://mma.prnewswire.com/media/1947468/Evogene.jpg
View original
content:https://www.prnewswire.com/news-releases/lavie-bio-announces-expansion-of-its-bio-inoculant-product-for-spring-wheat-yalos-to-durum-and-barley-301999031.html
SOURCE Lavie Bio